Table 1 Top-ranked compounds predicted to target OC cells based on subtype-specific enhancer landscapes.
OC subtype | Target | Drugs | Comments |
|---|---|---|---|
High-grade serous, clear cell and mucinous carcinomas | PPARG | Rosiglitazone, Pioglitazone Telmisartan, Rapamycin | Anti-diabetic and anti-inflammatory drugs. First two withdrawn from market in several countries |
ESR1 | Fulvestrant, estradiol, tamoxifen, afimoxifene | Oestrogen receptor modulators | |
NR3C1 | Mifepristone, hydrocortisone, dexamethasone | Anti-glucocortidoids and glucococorticoid medication | |
CTNNB1 | Sulindac, dinoprostone, indomethacin | Non-steroidal anti-inflammatories (NSAIDs) | |
High-grade serous carcinomas | CDK2 | Seliciclib, SNS-032 | Tested in vitro |
EHMT2 | Flavopiridol, BIX-01294, UNC0646 | Tested in vitro | |
EZH2 | Ademetionine, GSK503, GSK343 | Tested in vitro | |
Clear-cell carcinomas | SRC, CDK7 | Dasatinib, Alvocidib | — |
Mucinous carcinomas | NFYA, FOXH1 | Icosapent, Galzin | — |
